公开(公告)号：US10245267B2

公开(公告)日：2019-04-02

申请号：US15601423

申请日：2017-05-22

Applicant: NOVARTIS AG

Inventor： Robert John Aversa ,  Paul Andrew Barsanti ,  Matthew T. Burger ,  Michael Patrick Dillon ,  Alan Dipesa ,  Cheng Hu ,  Yan Lou ,  Gisele A. Nishiguchi ,  Yue Pan ,  Valery Rostislavovich Polyakov ,  Savithri Ramurthy ,  Alice C. Rico ,  Lina Quattrocchio Setti ,  Aaron Smith ,  Sharadha Subramanian ,  Benjamin R. Taft ,  Huw Roland Tanner ,  Lifeng Wan ,  Naeem Yusuff

IPC: C07D295/04 ,  A61K31/5377 ,  C07D413/04 ,  A61K31/541 ,  A61K45/06 ,  C07D213/74 ,  C07D237/20 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D277/42 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D493/10 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D213/75 ,  C07D233/88 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D241/20 ,  C07D471/04 ,  C07D487/04 ,  C07D263/58 ,  C07D491/107 ,  C07D493/04 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04 ,  A61K31/5375 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D237/22 ,  C07D409/14 ,  C07D491/048 ,  A61K31/444 ,  A61K31/501 ,  C07B59/00 ,  C07D237/24 ,  C07D491/04 ,  C07D491/08

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

公开(公告)号：US10709712B2

公开(公告)日：2020-07-14

申请号：US16274165

申请日：2019-02-12

Applicant: NOVARTIS AG

Inventor： Robert John Aversa ,  Paul Andrew Barsanti ,  Matthew T. Burger ,  Michael Patrick Dillon ,  Alan Dipesa ,  Cheng Hu ,  Yan Lou ,  Gisele A. Nishiguchi ,  Yue Pan ,  Valery Rostislavovich Polyakov ,  Savithri Ramurthy ,  Alice C. Rico ,  Lina Quattrocchio Setti ,  Aaron Smith ,  Sharadha Subramanian ,  Benjamin R. Taft ,  Huw Roland Tanner ,  Lifeng Wan ,  Naeem Yusuff

IPC: A61K31/5377 ,  C07D413/04 ,  A61K31/541 ,  A61K45/06 ,  C07D213/74 ,  C07D237/20 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D277/42 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D493/10 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D213/75 ,  C07D233/88 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D241/20 ,  C07D471/04 ,  C07D487/04 ,  C07D263/58 ,  C07D491/107 ,  C07D493/04 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04 ,  A61K31/5375 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D237/22 ,  C07D409/14 ,  C07D491/048 ,  A61K31/444 ,  A61K31/501 ,  C07B59/00 ,  C07D237/24 ,  C07D491/04 ,  C07D491/08

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

公开(公告)号：US09694016B2

公开(公告)日：2017-07-04

申请号：US14774431

申请日：2014-03-13

Applicant: Novartis AG

Inventor： Robert John Aversa ,  Paul Andrew Barsanti ,  Matthew Burger ,  Michael Patrick Dillon ,  Alan Dipesa ,  Cheng Hu ,  Yan Lou ,  Gisele Nishiguchi ,  Yue Pan ,  Valery Polyakov ,  Savithri Ramurthy ,  Alice Rico ,  Lina Setti ,  Aaron Smith ,  Sharadha Subramanian ,  Benjamin Taft ,  Huw Tanner ,  Lifeng Wan ,  Naeem Yusuff

IPC: C07D413/14 ,  C07D403/14 ,  C07D403/12 ,  C07D401/04 ,  A61K31/5377 ,  C07D413/04 ,  A61K31/541 ,  A61K45/06 ,  C07D213/74 ,  C07D237/20 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D277/42 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D417/12 ,  C07D493/10 ,  C07D401/14 ,  C07D405/14 ,  C07D213/75 ,  C07D233/88 ,  C07D405/04 ,  C07D405/12 ,  C07D241/20 ,  C07D471/04 ,  C07D487/04 ,  C07D263/58 ,  C07D491/107 ,  C07D493/04 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04 ,  A61K31/5375 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D237/22 ,  C07D409/14 ,  C07D491/048

CPC classification number: A61K31/5377 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5375 ,  A61K31/541 ,  A61K45/06 ,  C07B59/002 ,  C07B2200/05 ,  C07D213/74 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/84 ,  C07D233/88 ,  C07D237/20 ,  C07D237/22 ,  C07D237/24 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D241/20 ,  C07D263/58 ,  C07D277/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D491/107 ,  C07D493/04 ,  C07D493/10 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.